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Abstract
A new statistical method is introduced for dose ﬁnding in phase IB/IIA trials, which, along with
eﬃcacy and toxicity as endpoints, also considers pharmacokinetic information in the dose-selection
procedure. Following the assignment of a current best dose to a cohort of patients, the concentration
of a drug in the blood is measured at the locally D-optimal time points. The dose-response outcomes
are also observed for each patient. Based on the updated information, a new dose is selected for the
next cohort so that the estimated probability of eﬃcacy is maximum, subject to the condition that
the estimated probability of toxicity is not more than a chosen constant. Another condition for the
dose selection is related to the total exposure of the drug in the body, expressed by the area under the
concentration curve over time, so that the curative purpose is likely to be achieved in the population
without overdosing. Simultaneously to the maximisation of the estimated probability of eﬃcacy, the
mean area under the concentration curve for a chosen dose is not allowed to be more than a target value
taking into account its inter-patient variability. The purpose is to investigate the gain in eﬃciency of
using pharmacokinetic measures in the dose escalation. The proposed method is found to identify the
optimal dose accurately without exposing many patients to toxic doses.
Keywords: Area under the concentration curve, Continuation ratio model, D-optimum sampling
times, One-compartment pharmacokinetic model, Population pharmacokinetics.
1. Introduction
Interest has grown in recent years in the development of dose-ﬁnding methods incorporating both
toxicity and eﬃcacy as endpoints. The idea in these methods is to ﬁnd a dose for further development
which is both safe and eﬃcacious. Thall and Russell (1998) developed a dose-ﬁnding method that
satisﬁes both eﬃcacy and safety requirements. The method treats a suﬃcient number of patients, like5
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30 or 45, to estimate the rates of eﬃcacy and toxicity at the selected dose with a given reliability,
and also stops the trial if it is found that none of the doses are both safe and eﬃcacious. The dose-
response outcome in this case is trinomial, categorised as neutral, eﬃcacious or toxic, as in Li et al.
(1995). However, the method suﬀers from the limitation that, in the settings where all the doses have
acceptable toxicity with higher eﬃcacy at the higher doses, it does not escalate to the more desirable10
doses with high probability. So it often fails to detect the best dose in the presence of a number of
candidate doses. Thall and Cook (2004) proposed another method based on the trade-oﬀs between
treatment eﬃcacy and toxicity, which provides a substantial improvement over the earlier version and
also accommodates bivariate binary outcomes. The successive patients in a trial receive doses based
on a set of eﬃcacy-toxicity trade-oﬀ contours that partition the two-dimensional outcome space. The15
method is known as EﬀTox.
Zhang et al. (2006) proposed another such method considering trinomial responses. The design
selects a dose based on some optimal dose-selection criteria using the continual reassessment method
and is popularly known as TriCRM. Although the design follows a similar idea to that in Thall and20
Russell (1998), it uses the continuation ratio (CR) model with diﬀerent dose-selection criteria and
simpliﬁed stopping rules. Thall and Cook (2004) also extended the approach of Thall and Russell
(1998) to the CR model, but it involves considerable eﬀort to elicit priors. In that sense, TriCRM is a
simple alternative to EﬀTox.
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Dragalin and Fedorov (2006) suggested an adaptive procedure considering eﬃcacy and toxicity as
endpoints. The modelling of these bivariate binary endpoints is based on either Gumbel bivariate
binary logistic regression or the Cox bivariate binary model. They express a dose-ﬁnding problem in
terms of a penalised D-optimality criterion. The design maximises the information under the control
of a penalty function for treating patients at doses which are too low or too high. Thall et al. (2008)30
presented a dose-ﬁnding procedure based on bivariate outcomes that incorporates patients' covariates
and dose-covariate interactions. This is an extension of the methodology in Thall and Cook (2004).
Thall and Nguyen (2012) proposed a new approach for bivariate ordinal outcomes.
Phase I trials are small in size and as a consequence the dose-toxicity curves may not be well35
estimated. They often determine a dose which can be found either unacceptably toxic or ineﬀective in
a later phase. Phase I/II trials are relatively larger and so the associated methods could potentially
lead to more eﬃcient dose selection. They are still not big enough for the selected dose to converge
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to the best dose with probability one, even if the algorithm is shown to be convergent. The outcomes
in dose-ﬁnding studies are often dichotomised, and, as a result, we lose some information. In par-40
ticular, an outcome which is not toxic may be just below the cut-oﬀ point or a toxic outcome may
be far above the cut-oﬀ point. Similarly, the eﬃcacy is dichotomised. Usually these issues are not
considered in the dose-escalation methods. However, they can be considered implicitly by taking into
account continuous measures like the area under the concentration curve (AUC). This additional infor-
mation utilised during the process of dose selection may signiﬁcantly improve the eﬃciency of the trial.45
In this paper, we introduce a general approach for phase I/II trials, which, along with eﬃcacy
and toxicity endpoints, also considers pharmacokinetic (PK) information in the dose selection, the
information often viewed as important for ﬁnding the best dose (Govindarajulu, 1988). Although
there is considerable work on modelling PK and pharmacodynamic (PD) data, not much eﬀort has50
been devoted to incorporating PK information into adaptive dose-ﬁnding studies. Piantadosi and Liu
(1998) demonstrated that the eﬃciency and accuracy of phase I clinical trials can be improved by
incorporating PK data into dose escalation. Along with dose, they incorporated the resulting AUC
as a covariate in the model. The implementation of the method requires accurate PK data, but the
theory of optimal design to eﬃciently collect blood samples has not been used. Nyberg et al. (2009)55
considered simultaneous optimisation of dose and PK sampling times. A Bayesian approach for phase
I trials was presented in Whitehead et al. (2007), which is based on simultaneous monitoring of PK
and PD responses. The methodology in Zhou et al. (2008) is for phase I trials in healthy volunteers,
where, for each individual in the trial, the method monitors two continuous PK measures, AUC and
the maximum concentration, and a binary indicator variable for an undesirable event. The presented60
methods that incorporate PK measurements in dose escalation are for phase I trials. Since these are
usually small, it is diﬃcult to address the issue of population variability. In this paper, we propose a
dose-selection method for a seamless phase I/II clinical trial where it is possible to assess both toxic
and eﬃcacious outcomes. In such trials there is particular interest in the PK parameters and we use
the optimal sampling times for their precise estimation.65
Concentration of a drug in blood is generally modelled as a function of time for a given dose and the
PD eﬀect is often modelled as a function of dose. In a combined approach, the PD response is modelled
as a function of concentration. Concentration is inherently more informative than dose because, unlike
dose, which is only a nominal mass administered to a patient, it gives biological information (Riviere,70
2011). The PK/PD approach establishes the dose-concentration-eﬀect relationship and is capable of
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predicting the eﬀect at any time after administering a dose. It also helps in estimating the dose and
dosing interval to achieve the eﬀect of a desired level. The PK/PD approach has been described in
Meibohm and Derendorf (1997), Hooker and Vicini (2005), and Davidian (2010), among others. Since
characteristics such as age, body weight, ethnicity, physiological functions, genetics, disease status and75
sensitivity to treatment often vary from patient to patient, Jönsson (2004) developed methodologies
for individualised dosing utilising population PK and PK/PD models. These did not employ optimal
time points to collect the PK and PD responses, the use of which could save resources and provide
more accurate parameter estimates.
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More work is needed to increase the eﬃciency of clinical trials and here we present our attempt in
this direction. In this paper, we do not combine the PK and PD models into one. Instead, we use a
PD response to select the best dose with a restriction put on the drug exposure measured by the area
under the concentration curve. We consider two models, one for the dose-response outcomes and the
other for the PK data. We begin with an up-and-down design for the ﬁrst few cohorts, after which85
the model-based procedure starts. At that stage, we choose the dose which maximises the estimated
probability of eﬃcacy subject to the conditions that the estimated probability of toxicity at that dose
is not more than an acceptable level and also the estimated mean AUC is not more than a target
value. The latter constraint is deﬁned so that it includes the inter-patient variability in the AUC.
The analytical expressions for the AUC and its variability are based on the assumed PK model. The90
use of the AUC based on a separate PK model is simpler than the PK/PD approach. It gives precise
estimates of the PK parameters and leads to faster decision making regarding the dose. The aim
of this paper is to develop an eﬃcient dose-ﬁnding method that exposes not too many patients to ei-
ther sub-therapeutic or toxic doses and recommends the best dose for further study in phase IIB or III.
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The paper is organised as follows. Section 2 introduces the general algorithm for the new design,
the PK and dose-response models, and the dose-selection criteria and stopping rules. Section 3 presents
the simulation results comparing the new method with a special case of the one of Zhang et al. (2006).
Finally, there is a discussion in Section 4. Details of the up-and-down initial stage, model approximation
and derivation of the approximate mean and variance of the AUC are given in appendices.100
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2. Methods
2.1. Basic idea
We assume that a set of dose levels is pre-speciﬁed from pre-clinical trials or very early clinical trials.
The aim of the study is to select the dose level which can be recommended for further investigation
in a larger group of patients, where it is compared with a placebo or another experimental treatment.105
We consider here an adaptive design where an interim analysis of the data is performed after treating
each cohort of patients, and a new decision on the PK sampling times and on the dose allocation is
made for the next cohort based on the updated knowledge of the responses. As mentioned in Section
1, we support the choice of dose levels by additional information on the concentration of the drug
in the plasma, which is directly related to the dose response. Too high a concentration may cause110
toxicities while too low a concentration will not produce a desirable eﬀect. The dose-optimisation
criterion to be used in this paper is the maximisation of the estimated probability of eﬃcacy subject
to the constraints imposed on the estimated probability of toxicity at the selected dose and on the
estimated mean AUC. The population D-optimal blood sampling times assure high accuracy in the
estimation of the mean PK parameters and their variances. Our dose-response model is derived from115
a trinomial distribution for the outcomes: neutral, eﬃcacious and toxic. A one-compartment mixed
eﬀects model with bolus input and ﬁrst-order elimination is used for the PK data. In what follows,
we present the detailed forms of the considered models, both for the concentration of the drug and for
the drug eﬀect. However, we would like to stress that the algorithm is more general, that is, it can be
applied to other models as well, as it is indicated in Section 4.120
2.2. Optimum adaptive clinical trial design
We assume that the patients enter a clinic sequentially and cohorts of the same size are treated
with a dose level determined from the updated information. The choice of dose level for each cohort is
model based and satisﬁes an optimisation criterion. There are various possible criteria, such as maxi-
mum tolerated dose, biologically optimum dose or simply D-optimum dose. The maximum tolerated125
dose is the dose level for which the probability of toxicity attains a maximum permissible value. This
criterion is often used in oncology trials, as it is usually assumed that both the eﬃcacy and toxicity
probabilities increase with dose level. However, in cases where we can observe eﬃcacy, it makes sense
to consider a criterion which allows for the highest chance of eﬃcacy, particularly if it does not increase
with dose level. Alternatively, one can consider a criterion which in principle should lead to the best130
dose-response model prediction and so the best indication of the eﬃcacious dose level after the trial.
5
In this paper, we consider the biologically optimum dose approach, as, apart from recommending
an optimum dose for further studies, it generates dose levels during the trial considered as most eﬃ-
cacious, and thus gives a good chance of the best treatment for the patients in the trial. We escalate135
the dose level in the trial to maximise the chance of eﬃcacy, but not skipping too many dose levels,
while controlling the toxic events. This is done in two ways: by putting a constant threshold on the
probability of toxic outcomes and by restricting the total exposure of the drug in the body. The former
restriction is based on a dichotomised response, yes or no for a toxic event, over a cohort, while the
latter one is based on a continuous PK measure, the population mean AUC. This additional informa-140
tion needs to be as accurate as possible and so we derive population D-optimum designs for blood
sampling times for each cohort of patients. This gives us very precise estimates of the PK parameters
at each stage of the adaptive trial.
Below we present the main steps of the adaptive design, where k represents the stage in a trial.145
Step 1: Treat cohort k with the current best dose.
Step 2: Obtain the D-optimal sampling time points and observe the PK responses at these time
points, when appropriate.
Step 3: Observe the dose-response outcomes.
Step 4: Estimate the model parameters and update the models.150
Step 5: Select the best dose for the next cohort based on the chosen dose optimisation criterion and
constraints.
Step 6: Stop if the stopping rule is met, otherwise set k = k + 1 and repeat Steps 1-5.
Step 7: Carry out a complete analysis of the data to recommend a dose for further study.
155
We need to estimate the PK parameters as well as the dose-response parameters at each stage of
the adaptive trial. With a small cohort size, we need to collect data from a few cohorts to obtain
some reliable parameter estimates. Hence, we start the trial with an up-and-down procedure, which is
run for the ﬁrst few cohorts before we start the fully adaptive parametric algorithm described above.
During the up-and-down procedure, we observe the PK responses and the dose-response outcomes, but160
there is no estimation of parameters. The up-and-down procedure is similar to that of Ivanova (2006),
where a dose is increased, stays at the present dose or is decreased depending on the responses of the
most recent cohort. Here, however, we take into account responses from all cohorts up to the most
recent one. The basis of the method lies in the toxic outcomes, which can stop the trial if toxicity is
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above the acceptable level. Details of this initial part of the trial are given in Appendix A.165
In Section 3, we conduct a simulation study to illustrate the operating characteristics of the pro-
posed design. The example used consists of the one-compartment PK model with random eﬀects and
the continuation ratio dose-response model, described in Sections 2.3 and 2.4, respectively.
2.3. Population PK model170
We consider PK models for the concentration of a drug in the plasma. Often, the mechanistic part
of such models is a solution of diﬀerential equations representing the distribution of the drug in the
body's compartments. The drug is absorbed, distributed and eliminated, and these processes diﬀer
among patients. Hence, so-called population PK models need to be considered to account for this
variability.175
We denote the population PK models by
yij = f(θi, tij) + ij , i = 1, . . . , N, j = 1, . . . , ni, (1)
where yij is a random variable representing the concentration of a drug in the blood for the ith individ-
ual at time tij , θi is a p-dimensional vector of the model parameters for the ith individual, f : R+ → R+
is a function which is non-linear with respect to the parameters and possibly also with respect to the
design variable t, ij denotes the random error and ni is the number of measurements taken on indi-180
vidual i. An additive random error model may lead to negative concentrations in the simulation study
with large error observations. However, it works well in the presence of a small error variance. For a
large error variance, it would be wise to consider a multiplicative error model yij = f(θi, tij) exp(ij),
so that log(yij) = log(f(θi, tij))+ij . The methodology presented in this paper can be applied to both
cases with some minor technical adjustments to the model approximation.185
Furthermore, we assume that some or all of the model parameters are random and can be rep-
resented in an additive form as θi = β + bi, where β = (β1, . . . , βp)
T is a vector of the population
mean parameter values and bi is a vector of random eﬀects for subject i. We assume that bi has a
multivariate normal distribution with zero mean vector and diagonal covariance matrix denoted by
E(bi) = 0 and Var(bi) = Ω = diag(ω1, . . . , ωp).
We also assume that the random errors are independently normally distributed with zero mean and
constant variance σ2 and that bi and i are independent. Retout et al. (2001) also assumed an additive
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model for the random parameters. Although the normality assumption may lead to negative values
of the parameters, this will be very rare unless the variability in the parameters is very large. This190
possibility can be avoided if an exponential model θi = β exp(bi) is assumed instead. Here, we consider
the additive random parameters to keep the PK model simple. However, a switch to the exponential
model would not alter the dose-ﬁnding methodology presented here.
We are interested in the eﬃcient estimation of all the population parameters, denoted by Ψ =
(βT,λT)T, where βT = (β1, . . . , βp) and λ
T = (ω1, . . . , ωp, σ
2). The dimension of Ψ is 2p + 1 if all
the parameters are random, otherwise it will be less. The Fisher information matrix (FIM) for the ith
individual and design ξi = {ti1, . . . , tini} is given by
Mi(Ψ, ξi) = E
{
−∂
2li(Ψ | yi)
∂Ψ∂ΨT
}
, (2)
where li(Ψ | yi) is the log-likelihood function for a given vector of observations yi = (yi1, . . . , yini)T195
for individual i. Since our model is non-linear in the parameters, derivation of an analytic expression
for the log-likelihood function is not possible. Various approximations to the information matrix have
been proposed in the statistical literature. A comparison of diﬀerent methods is presented in the PhD
thesis by Mielke (2012), who concludes that none of the methods is uniformly best.
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As in Pinheiro and Bates (1995) or Retout et al. (2001), we approximate the log-likelihood function
using a ﬁrst-order Taylor series expansion of the function f(θi, tij). Here, however, we expand the
function about φi = (β
T, bTi )
T at φ0 =
(
β0
T
,E(bi)
T
)T
=
(
β0
T
,0T
)T
, where β0 is a vector of initial
values for the population means: see Appendix B. The population FIM for the design for all subjects
in the trial Ξ = {ξ1, . . . , ξN} is deﬁned as the sum of the N individual Fisher information matrices in
(2), that is,
M(Ψ,Ξ) =
N∑
i=1
Mi(Ψ, ξi).
The FIM is an argument of many optimal design criteria, initially derived for ﬁxed eﬀects lin-
ear models, but more recently extended to non-linear models by Fedorov (1972); Fedorov and Hackl
(1997), and Atkinson et al. (2007), including random eﬀects, as in Mentré et al. (1997). In this work,
we use the D-optimality criterion, that is, we maximise the determinant of the population FIM to
obtain sampling times for measuring the concentration of the drug in the plasma. The properties of205
this criterion are well known and it is widely used in many applications. We ﬁnd that our estimates
of the PK model parameters are very precise, as one would expect from data collected according to
a D-optimum design. Computations for the D-optimal time points are implemented in PFIM 3.2
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(Bazzoli et al., 2010), an R package to evaluate and optimise designs in the context of population PK
experiments.210
Since the FIM depends on the model parameters, to obtain the locally optimal time points we
need to assume some prior values for the parameters. The procedure starts with some informed guess
of the parameters and then replaces them at each stage with the current maximum likelihood esti-
mates. The covariance matrix of the maximum likelihood estimators approaches the inverse of the215
FIM asymptotically. Therefore, by minimising the inverse of the determinant of FIM, the D-criterion,
we can minimise the asymptotic general variance of the estimated model parameters. To achieve this,
we obtain the maximum likelihood estimates using the R procedure nlme (Pinheiro and Bates, 2000).
It is also possible to use the posterior estimates of the PK parameters in the search for the optimal
time points, but that would involve more computational challenges and would require assumptions220
regarding prior distributions of the parameters. Wakeﬁeld et al. (1994) developed a Bayesian approach
for the non-linear mixed-eﬀects model. They used a three-stage model and a Markov Chain Monte
Carlo method to obtain the posterior density of the random eﬀects, and hence the posterior estimates.
Apart from precise estimation of the model parameters and model prediction, we are interested225
in using the PK information for guiding an adaptive dose-selection procedure. A patient's response
depends on the exposure to the drug. Hence, we use the AUC of the PK proﬁle as a measure in the
guidance. Other measures could also be considered, such as the maximum concentration or the time
to maximum concentration. Although we focus here on the AUC, it is straightforward to adapt the
algorithm to another measure.230
Let h(x,θi) represent the AUC for individual i, where x is the dose received, θi is the vector of
random PK parameters and h is a diﬀerentiable function of the parameters. Then the concentration
curve is a random variable. To derive approximations to its expectation and variance, we use a ﬁrst-
order Taylor series expansion of h(x,θi) about θi at E(θi): see Appendix C. The expression derived235
here for measuring the inter-patient variability in the area under the concentration curve is general.
The methodology can be adapted for the maximum concentration, another important PK parameter,
and, of course, for any underlying PK model.
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Example
Consider the simple one-compartment PK model with bolus input and ﬁrst-order elimination. Then
model (1) becomes
yij =
x
Vi
exp
(
−Cli
Vi
tij
)
+ ij , i = 1, . . . , N, j = 1, . . . , ni,
where Cli and Vi denote the clearance and volume of distribution for individual i, so that θi = (Vi, Cli)
T
240
is the vector of parameters, with β = (V,Cl)T and bi = (bV i, bCli)
T. It is shown in Appendix C that
the approximate mean and variance of the AUC over the range [0, t1] are
E{h(x,θi)} ∼= h(x,β) = x
Cl
{
1− exp
(
−Cl
V
t1
)}
(3)
and
Var{h(x,θi)} ∼=
{
xt1
V 2
exp
(
−Cl
V
t1
)}2
ω1 +
{
x
Cl
exp
(
−Cl
V
t1
)(
1
Cl
+
t1
V
)
− x
Cl2
}2
ω2. (4)
These approximations are used in the adaptive dose-selection procedure, which is described in
Section 2.5.245
2.4. Dose-response model
We consider a trinomial response Y = (Y0, Y1, Y2)
T for each patient, where Y0 is a neutral response,
Y1 is an eﬃcacious response and Y2 is a toxic response. The probability of each of these outcomes
depends on dose. It is commonly accepted that a drug's toxicity increases with dose. Eﬃcacy also
increases in many cases, but it is possible for some drugs that the eﬃcacy attains a plateau or in-250
creases and then decreases. For an experimental drug, we assume that the probability of a neutral
response decreases monotonically with dose and that the probability of toxicity increases monotoni-
cally with dose. However, the probability of an eﬃcacious outcome may be non-monotonic, increasing
or decreasing. The corresponding probabilities are denoted by ψ0(x,ϑ), ψ1(x,ϑ) and ψ2(x,ϑ), so that
ψ0(x,ϑ) + ψ1(x,ϑ) + ψ2(x,ϑ) = 1, where ϑ is the vector of parameters.255
The proportional odds model is often used to establish the dose-response relationship in such a
situation. However, it requires the assumption that dose has the same eﬀect across the cumulative
logits. Since this assumption is very diﬃcult to satisfy, we plan to utilise the continuation ratio model
(Agresti (1990), Chapter 9) given by260
log
{
ψ1(x,ϑ)
ψ0(x,ϑ)
}
= ϑ1 + ϑ2x and log
{
ψ2(x,ϑ)
1− ψ2(x,ϑ)
}
= ϑ3 + ϑ4x.
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The parameter ϑ1 represents the baseline log-relative probability, ϑ2 reﬂects the contribution of
dose in the log-relative probability of having an eﬃcacious outcome relative to a neutral one, ϑ3 is the
baseline log-odds and ϑ4 is the contribution of dose in the log-odds of a toxic outcome relative to a
neutral or eﬃcacious one. Solving the above equations, we obtain
ψ0(x,ϑ) =
1
(1 + eϑ1+ϑ2x)(1 + eϑ3+ϑ4x)
,
ψ1(x,ϑ) =
eϑ1+ϑ2x
(1 + eϑ1+ϑ2x)(1 + eϑ3+ϑ4x)
and265
ψ2(x,ϑ) =
eϑ3+ϑ4x
1 + eϑ3+ϑ4x
.
To ensure that the above three non-linear functions exhibit the assumed behaviour of the responses,
we restrict the parameter space to
Θ =
{
ϑ = (ϑ1, ϑ2, ϑ3, ϑ4)
T : ϑ1 ≥ ϑ3, ϑ3 < 0 and ϑ2, ϑ4 > 0
}
.
Assume that we are at the kth stage in a trial. So k cohorts have been treated so far with dose
levels from the set of ordered levels X . Let x be the k × 1 dose vector with components xl and let
R be the k × 3 outcome matrix with Rl = (Rl0, Rl1, Rl2) as the lth row, l = 1, 2, . . . , k. Note that270
Rl0 +Rl1 +Rl2 = c, where c is the number of subjects in a cohort treated with dose xl. The successive
components of Rl are the counts of neutral, eﬃcacious and toxic responses for the lth cohort. Thus,
the likelihood function is
Lk(ϑ | x,R) ∝
k∏
l=1
{ψ0(xl,ϑ)}Rl0{ψ1(xl,ϑ)}Rl1{ψ2(xl,ϑ)}Rl2 .
The parameters ϑ are estimated at each stage of the adaptive trial. Since maximum likelihood
estimation is unsuitable because of small sample sizes at the early stages of the trial, we employ a275
Bayesian approach. The posterior estimate of ϑ at the kth stage is
ϑˆk =
∫
Θ
ϑ p(ϑ)Lk(ϑ | x,R)dϑ∫
Θ
p(ϑ) Lk(ϑ | x,R) dϑ , (5)
where p(ϑ) is the joint prior distribution of the parameters. Let us assume that 0 < ϑ2 < u1,
0 < ϑ4 < u2, w1 < ϑ1 < w2 and w3 < ϑ3 < w4, and that the joint prior distribution is uniform. Then
we obtain
p(ϑ) =
2
u1u2(w2 − w3)2 , ϑ ∈ Θ˜, (6)
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where280
Θ˜ = {ϑ : w3 < ϑ3 ≤ ϑ1 < w2, 0 < ϑ2 < u1, 0 < ϑ4 < u2} . (7)
In Section 3, we choose a diﬀerent Θ˜ for each of the simulation scenarios.
2.5. Dose-selection criteria
At each stage in the trial, we select that dose for the next cohort for which the estimated probability
of eﬃcacy is maximum, subject to the condition that the estimated probability of toxicity is not more
than a pre-speciﬁed acceptable level. Often, it is not advisable to skip the pre-speciﬁed dose levels285
when they are increased for application in the next cohort. In our method, we introduce an option
of constraining the increase by any number of dose levels. However, we impose no such constraint on
the levels when they are decreased. For example, the next best dose could be ﬁve levels higher then
the previous one, but with a constraint of not skipping more than one dose level, we apply the dose
two levels higher than the previous one. Another condition for the dose selection is related to the290
total exposure of the drug in the body so that the curative purpose is likely to be achieved without
overdosing; this is expressed by a restriction on the area under the concentration curve over time.
Suppose that we are at the kth stage of the trial and based on the current data, we have the
estimates Ψˆk and ϑˆk. Then, we select the dose xk+1 for the next cohort of patients so that295
xk+1 = arg max
x∈X
ψ1(x, ϑˆk),
subject to the conditions that
ψ2(xk+1, ϑˆk) ≤ γ
and
Eˆ{h(xk+1,θi)} −AUC0
ŜD{h(xk,θi)}
≤ δ(xk, ϑˆk), (8)
where γ ∈ (0, 1) is a given constant, usually allowing 20-30% chance of toxicity and Eˆ{h(x,θi)} =
h(x, βˆk) is the estimate of the approximate population mean AUC for dose x at stage k. The estimate
of the approximate standard deviation of the AUC is denoted by ŜD{h(xk,θi)}. Also, AUC0 is a value300
for the AUC that is considered to be desirable and δ(xk, ϑˆk) = 1/ψ1(xk, ϑˆk). A desirable AUC is
one for which the curative purpose is likely to be achieved, allowing some acceptable level of toxicity.
The choice of such a value will require expert opinion. Previous studies of similar drugs or pre-clinical
12
studies can help in this context.
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The left-hand side of (8) represents a relative diﬀerence between h(xk+1, βˆk) and AUC
0. We con-
strain the choice of xk+1 so that, for large values of the estimated probability of eﬃcacy ψ1(xk, ϑˆk),
this diﬀerence is small. This `forces' convergence of the dose to the one giving the required exposure
to the drug. On the other hand, when the estimated probability of eﬃcacy is small, the constraint
is weak, allowing for a wider choice for the next dose level. The PK constraint (8) is dynamic, that310
is, the value of δ(xk, ϑˆk) changes during the trial according to the current estimate of the probability
of eﬃcacy, and the estimates of the expectation and the standard deviation of the AUC are updated
after each cohort. This gives some ﬂexibility to the algorithm. A ﬁxed δ might lead to choosing a
sub-optimal dose, and, in any case, it would be diﬃcult to decide on its value.
315
It follows from the constraint that Eˆ{h(xk+1,θi)} ≤ AUC0 +δ(xk, ϑˆk) ŜD{h(xk,θi)}. If ψ1(xk, ϑˆk)
attains the maximum possible value 1, then δ(xk, ϑˆk) will have the value 1 and consequently we will
choose a dose with a mean AUC within one standard deviation of the target, which accommodates the
population variability. However, in the majority of cases, δ will have a larger value than 1. Therefore,
we will usually be selecting a dose with a mean AUC within more than one standard deviation of the320
target value.
This constraint is introduced as an additional indicator of a curative eﬀect, with a precaution
against the allocation of too toxic doses. It works diﬀerently to the constraint on the probability of
toxicity ψ2. The AUC, expressed as a function of the random PK parameters, not only takes into325
account the population variability, but also directly constrains the PK parameters responsible for the
drug's action, and so indirectly, the dose level.
2.6. Stopping rules
In a clinical trial, a variety of stopping rules are possible and the choice depends on the purpose
of the trial. We employ a simple rule: stop the trial when the same dose is repeated for r cohorts330
or when the trial reaches the maximum number of m cohorts, whichever comes ﬁrst. The idea is to
terminate the trial early to save resources if it is found that the same dose is being selected repeatedly.
Otherwise, it will run for the maximum number of cohorts available. For early stopped trials, the
optimum dose (OD) is deﬁned as the dose that has been repeated r times. However, for the trials that
use the maximum number of cohorts m, we carry out a complete analysis of the data and deﬁne the335
OD as the dose that would be allocated to cohort m+ 1 if that cohort were in the trial.
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3. Simulation results
3.1. Choice of design parameters
We assume that an experimental drug has 20 available doses from 0.5 to 10, increasing in steps of
0.5, that is, the set of doses is X = {0.5, 1.0, . . . , 10.0}. Four hypothetical dose-response scenarios are340
considered: see Figure 1. Scenario 1 has a monotonically decreasing eﬃcacy curve with dose 0.5 as
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Figure 1: Dose-response scenarios for simulation study. The respective parameter values are: Scenario 1, ϑ =
(1.44, 0.26,−1.70, 0.25)T; Scenario 2, ϑ = (−3.50, 1.00,−6.00, 0.72)T; Scenario 3, ϑ = (−0.80, 0.50,−3.80, 0.30)T; and
Scenario 4, ϑ = (−6.50, 0.75,−8.00, 0.65)T.
the OD. Scenarios 2 and 3 depict non-monotonic eﬃcacy curves with respective ODs of 5.5 and 6.5.
A monotonically increasing eﬃcacy curve is reﬂected in Scenario 4 with 10 as the OD. Two kinds of
responses need to be generated for the simulation study: the concentration of the drug in the blood
and the trinomial dose-response outcomes. The values of the PK parameters for the simulation study345
are V = 0.5 L, Cl = 0.06 L/hr, ω1 = 0.004, ω2 = 0.00005 and σ
2 = 0.000225. The parameter values
are chosen such that the coeﬃcient of variation is around 12%. The choice of a small error variance
should be reasonable as we have found the observations to be small as well.
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Each trial starts with the lowest dose of 0.5 mg/kg body weight. The acceptable toxicity level γ is350
taken to be 0.20. Doses to the ﬁrst four cohorts in each trial are allocated according to the up-and-
down design in Appendix A. The up-and-down stage need not have exactly four cohorts. There are
ﬁve parameters to estimate in our PK model and, therefore, we have chosen four cohorts to provide
initial values for the maximum likelihood estimates. One should choose this number depending on the
complexity of the model. The value of AUC0 is taken to be the AUC at the true OD in each scenario.355
Although we consider the same γ for each scenario, we have diﬀerent values of AUC0. The highest
doses which meet the safety level are 1 mg/kg, 6 mg/kg, 8 mg/kg and 10 mg/kg for the respective
scenarios. For each trial, we set the maximum number of cohorts to be m = 20, each cohort of size 3.
To let the trials stop early when it is found that no further improvement in dose selection is possible,
we set r = 6.360
3.2. Generation of PK and dose-response outcomes
A vector of random eﬀects bi for individual i is generated from the bivariate normal distribution
N2(0,Ω). The PK parameters for that individual are then obtained as θi = β + bi. The next step is
to ﬁnd the individual concentrations at the D-optimal time points. The design region for the sampling
times is T = [0, t1] hours, where t1 = 30 in (3). To decide on the optimal number of sampling times,365
we use the relative eﬃciency deﬁned in (9). Although we consider the same prior in each case, the
designs have a diﬀerent number of design points. It has been found that the eﬃciency of a 3-point
design relative to a 2-point one is double. The eﬃciency of a 4-point design relative to a 3-point one
falls to 1.15. As we increase the number of design points, such eﬃciencies become closer to 1: see
Figure 2. This means that the gain is substantial if we consider 3 design points rather than 2.
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Figure 2: Rationale for setting the number of design points in the one-compartment PK model with bolus input and
ﬁrst-order elimination. The locally D-optimum design points are obtained using the initial prior values Ψ0 assuming
that the lowest dose is given to a cohort of 3 patients.
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Therefore, to avoid the diﬃculty of collecting many samples, three optimal time points are consid-
ered for the individuals in each cohort, that is, ni = 3 for all i. The random errors are then generated
from N3(0, σ
2I3) and added to the previously generated individual concentrations to produce the sim-
ulated PK responses for individual i. The same scheme is followed to simulate the responses for all
individuals in each cohort. We chose the prior values Ψ0 = (0.1, 0.005, 0.0007, 0.0000006, 0.000004)T375
to obtain the optimal points for the ﬁrst four cohorts in the up-and-down stage of the trial. The prior
values are quite far away from the true values of the parameters, which would normally be unknown
and could be wrongly assumed at the beginning of the trial. For the ﬁfth cohort onwards, the current
maximum likelihood estimates of the PK parameters are used.
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Figure 3: Simulated concentrations in a randomly chosen trial for Scenario 3.
Figure 3 gives the concentration data that are obtained in a randomly chosen trial for Scenario 3380
from the simulation study of 1000 simulated trials. A total of 60 patients are recruited in this particular
trial and the concentrations at the three D-optimal time points are shown for each patient and are
denoted by circles. Though not presented, the other scenarios would have similar kind of concentration
data. The progress of the same trial is summarised in Figure 4. Under each of the scenarios in Figure
1, we have speciﬁc probabilities at each dose to generate the trinomial dose-response outcomes. The385
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Figure 4: Summary of the progress in a random trial for Scenario 3.
outcomes obtained for each cohort of the presented trial are plotted against their numbers. Each dotted
horizontal line that goes through the middle of the outcomes indicates the dose that the corresponding
cohort received.
3.3. Model ﬁtting
Once we have data on the concentration and the dose-response outcomes, we can update the390
model ﬁts. We obtain the maximum likelihood estimates of the PK parameters using the R procedure
nlme (Pinheiro and Bates, 2000). The posterior estimates of the dose-response parameters in (5),
are obtained by numerical integration using cubature, an R package (Johnson and Narasimhan, 2009).
The package carries out the adaptive multidimensional integration over hypercubes. One needs to
specify the tolerance limit and the maximum number of function evaluations desired. The smaller395
the tolerance limit or the larger the maximum number of function evaluations, the more accurate the
estimate is. We set these to be 0.001 and 5,000, respectively, to keep the computational time down.
We use a joint uniform prior distribution for ϑ, given in (6). The parameter space Θ˜ is chosen for each
scenario so that the true values of the parameters lie in the middle of the corresponding intervals. For
instance, since Scenario 1 has the true parameters ϑ = (1.44, 0.26,−1.70, 0.25)T, Θ˜ has 0 < ϑ2 < 0.52,400
0 < ϑ4 < 0.50, 0 < ϑ1 < 2.88 and −3.40 < ϑ3 < 0. More speciﬁcally, u1 = 0.52, u2 = 0.50, w1 =
0, w2 = 2.88, w3 = −3.40 and w4 = 0 in (7). The same approach is followed for the other scenarios.
In evaluating the integrals in (5) with the uniform distribution speciﬁed in (6), the prior distributions
in the numerator and denominator cancel out as they are constants. Once the posterior estimates are
obtained, we update the dose-response functions.405
3.4. Dose selection for the next cohort
Once we have the updated PK and dose-response parameter estimates, we can select the dose for
the next cohort based on the criteria deﬁned in Section 2.5. As an additional safety precaution, we
17
allow the design to skip only one level at a time when the dose is increased.
3.5. Checking the stopping rules and the OD selection410
We continue the process of allocating doses to the cohorts until the stopping rules are satisﬁed.
Once a trial reaches m cohorts, we carry out a complete analysis to ﬁnd the OD. At the end of each
trial, we also record the PK and dose-response parameter estimates, whether the trial stopped early
and the OD in that case. Each of the four scenarios is investigated through 1,000 simulated trials.
All the computations are conducted in R. The simulations are implemented on a Dell PC with an415
Intel Core 2 Duo processor running at 3.00 GHz and RAM 4.00 GB. The processing time for 1,000
simulations is 8-10 hours.
3.6. Numerical results
We compare the operating characteristics of the new PK guided design, incorporating the AUC
constraint, with the one that does not take into account the PK information. The dose selection in the420
latter design is based on the probability of eﬃcacy and the toxicity condition only, deﬁned in Section
2.5. It is similar to the method presented by Zhang et al. (2006). The simulation results for these two
designs are presented in Table 1 and Figures 5-11. In Figures 5-8, the ﬁrst row shows the summaries
when the additional PK constraint is employed. The summaries in the second row are based on the
toxicity constraint only.425
Table 1 clearly shows the advantages of the additional constraint on the AUC proﬁle. The gain in
percentage of the doses correctly recommended for further studies depends on the scenario, but, in all
cases considered, the PK guided designs are uniformly better in this respect.
430
Table 1: Percentage of best doses recommended as optimum for further studies (%BD), percentage of doses recommended
as optimum for further studies, but carrying the probability of toxicity above the acceptable level (%TD), and percentage
of cohorts treated at the best doses throughout the trials (%AD).
Scenario Best Doses %BD %TD %AD
PK No PK PK No PK PK No PK
1 0.5 99.0 52.4 0.6 32.7 65.3 31.8
2 5.5 and 6.0 80.2 66.2 0.9 9.5 41.1 33.5
3 5.5-7.5 91.7 85.7 0.0 2.5 52.4 49.2
4 10.0 47.9 46.3 0.0 0.0 17.8 17.5
18
As seen in Table 1, as well as in the left panels of Figure 5, the largest beneﬁt is shown in Scenario
1, where the best dose is the ﬁrst one and small doses have a high probability of toxicity. The right
panels of this ﬁgure show how the doses were allocated in the simulated trials. The new approach
selects 0.5 as the OD in 99% of the trials, compared to 52.4% by the old approach. Only in 0.6% of
the trials was a dose with a probability of toxicity above the limit γ chosen as the optimum in the435
PK guided trial, whereas it was 32.7% in the other case. Therefore, the PK guided design avoids
doses with a high chance of toxicity, while the other design has not prevented this from happening.
Furthermore, 65.3% of the cohorts were treated at the best dose in the PK guided trials, compared to
only 31.8% in the trials without the PK guidance.
440
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Figure 5: Scenario 1 with the OD at 0.5. The bars in the left panel represent the proportions of the doses selected as
the OD in the simulations and those in the right panel represent the proportions of the cohorts treated at the allocated
doses during the trials. The acceptable level for the probability of toxicity is indicated by the horizontal dashed line.
The new approach in Scenario 2 selects 5.5 as the OD in 39.7% of the trials. It selects dose 6.0 in
40.5% of the trials. This happens as the true probabilities of eﬃcacy at these doses are quite close.
These two ﬁgures together make 80.2% of what we call in Table 1 best doses. The corresponding ﬁg-
ure for the old approach is 66.2%. Again, we observe that the PK guided design avoids recommending
19
doses with a high probability of toxicity, and, moreover, such doses are used much less in the simulated445
trials in this case: see Figure 6.
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Figure 6: Scenario 2 with the OD at 5.5. The bars in the left panel represent the proportions of the doses selected as
the OD in the simulations and those in the right panel represent the proportions of the cohorts treated at the allocated
doses during the trials. The acceptable level for the probability of toxicity is indicated by the horizontal dashed line.
The new approach in Scenario 3 identiﬁes exactly 6.5 as the OD in 17.8% of trials. Because of the
ﬂat shape of the eﬃcacy curve, this scenario has a number of doses with probabilities of eﬃcacy quite
close to that for the OD. The doses are 5.5, 6.0, 6.5, 7.0 and 7.5, and these best doses are selected in450
91.7% of trials. Although the old approach selects these doses in 85.7% of trials, it recommends doses
above the toxicity probability threshold in 2.5% of cases. Furthermore, from Figure 7, the allocation
of doses in the trials is again more ethical in the PK guided design.
There is little diﬀerence between the two designs in Scenario 4, as shown in Table 1 and also in455
Figure 8. The new approach selects 10.0 as the OD in 47.9% of the trials, while the percentage for
the old approach is 46.3. This is the case where both the probability of eﬃcacy and the probability of
20
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Figure 7: Scenario 3 with the OD at 6.5. The bars in the left panel represent the proportions of the doses selected as
the OD in the simulations and those in the right panel represent the proportions of the cohorts treated at the allocated
doses during the trials. The acceptable level for the probability of toxicity is indicated by the horizontal dashed line.
toxicity increase with dose, where only higher doses have a better chance of having an eﬀect and all
doses are below the toxicity threshold. This scenario illustrates a very cautiously chosen dose range. As
a consequence, this leads to slow learning in the trial and requires the collection of a lot of information460
before a recommendation can be made.
We have found that, for this scenario, all available cohorts were used almost all the time. This
is in contrast to Scenario 1, where, especially in the PK guided design, the learning process was fast
and there were much smaller numbers of cohorts required in the trials. In fact, Scenario 1 is another465
extreme case, where the dose range is not well chosen. Smaller dose levels in this case could have been
even better and the trial carries a high risk of toxic responses.
Figure 9 shows the distribution of the PK parameter estimates for all the scenarios. We have found
the coeﬃcient of variation for the mean PK parameter estimates to be around 2%, and those for the470
variance components and error variance to be 10-35%, except for Scenario 1 where it is high for the
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Figure 8: Scenario 4 with the OD at 10.0. The bars in the left panel represent the proportions of the doses selected as
the OD in the simulations and those in the right panel represent the proportions of the cohorts treated at the allocated
doses during the trials. The acceptable level for the probability of toxicity is indicated by the horizontal dashed line.
error variance because of the presence of some outliers in the estimates. Since the design employs
the D-criterion for measuring PK responses, it is assuring high eﬃciency in the parameter estimation.
From Figures 10 and 11, the dose-response parameter estimates obtained from the two approaches
are similar. Obviously, they are not as good as the PK estimates. This is due to the fact that the475
information on the trinomial dose response is not gathered in a way that would be optimal for param-
eter estimation. Here, we focused on the criterion which would provide a good dose for further studies
in an ethical trial, which is particularly important in classes of drugs where toxicity can be very serious.
It has already been mentioned that we stop a trial early if the same dose is repeated for six cohorts480
and call the associated dose the OD. We have found that, as the location of the OD moves from left to
right in the dose region of a scenario, more cohorts are needed to stop early. Most of the early stopped
trials identify the OD accurately. It has been found that the PK guided approach utilises fewer cohorts
than the other approach.
22
485
0.
48
0.
52
V
Es
tim
at
es
0.
05
6
0.
06
0
0.
06
4
Cl
0.
00
2
0.
00
6
ω1
0e
+0
0
4e
−0
5
8e
−0
5
ω2
0.
00
0
0.
00
2
σ2
Figure 9: Boxplots of the PK parameter estimates obtained from the simulations. The horizontal dashed lines indicate
the true parameter values. For each parameter, the successive boxes are for Scenarios 1, 2, 3 and 4, respectively.
To investigate the sensitivity of the PK sampling times to the assumed prior values, we deﬁne the
relative D-eﬃciency of a design ξ∗k to ξ
∗
true as
Relative Efficiency =
(
|M(Ψˆk, ξ∗k)|
|M(Ψtrue, ξ∗true)|
) 1
p
, (9)
where ξ∗k is the optimum design obtained at the kth stage of a trial using the current estimates of
the parameters Ψ, ξ∗true is the optimum design obtained for the true values of the parameters and p
is the number of parameters in the model. In both cases, the dose remains ﬁxed and it is the one490
administered to the cohort at the kth stage. Since both designs depend on the parameter values, it
is possible, with completely diﬀerent parameter values to the true ones, to have a design for which
the relative eﬃciency is very high. A larger determinant of the information matrix means a smaller
generalised variance of the estimators. But, in our case, that will mean that the variance is underes-
timated. Hence, we want the numerator to be close to the denominator in (9). This, in turn, means495
that we want to have an optimum design which is obtained for values around the true values of the
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Figure 10: Boxplots of the dose-response parameter estimates obtained from the simulations, the top panel for Scenario 1
and the bottom panel for Scenario 2. The horizontal dashed lines indicate the true parameter values. For each parameter,
the left box corresponds to the design which takes into account the AUC and the right box to the one which ignores it.
parameters. This can be achieved in a trial as we update the parameter estimates at each stage. After
a suﬃcient number of stages, the estimates will be stable and so will be the design points: see Figure 12.
Figure 13 shows the relative D-eﬃciency of the designs computed at each of the stages using (9)500
for Scenario 2. Though not presented, we have found underestimated variances for the initial four
stages. Recall that we use the up-and-down design for the ﬁrst four cohorts and that blood samples
for these cohorts are collected at the optimal time points which are based on an initial guess about
the parameter values. From the ﬁfth cohort onwards, we use the current estimates obtained from the
trial data. Here, we observe a decreasing trend in the relative eﬃciency. Since the estimates stabilise505
as the trial proceeds, there is not much change at the later stages and also the eﬃciency approaches one.
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Figure 11: Boxplots of the dose-response parameter estimates obtained from the simulations, the top panel for Scenario 3
and the bottom panel for Scenario 4. The horizontal dashed lines indicate the true parameter values. For each parameter,
the left box corresponds to the design which takes into account the AUC and the right box to the one which ignores it.
The PK guided design depends on the target value of the AUC. In our simulations so far, we have
considered it as the one at the true OD. To assess the sensitivity of the design to the target value,
we set it at doses other than the true OD. All of the scenarios are studied for this purpose. Table 2510
gives a summary of the results. The notation in these tables is deﬁned as follows: dose used for cal-
culating AUC0 (Dose), percentage of best doses recommended for further study (%BD), percentage of
doses recommended as optimum, but carrying the probability of toxicity above the maximum allowed
threshold (%TD), and percentage of cohorts treated at the best doses throughout the trials (%AD).
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The ﬁgures in the tables indicate that the design is sensitive to the choice of target value for the
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Figure 12: Optimal PK sampling time points in a trial. The left plot shows the points for the true values of the PK
parameters and the one on the right gives the points using the current estimates.
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Figure 13: Relative D-eﬃciency in a randomly selected trial for Scenario 2.
AUC. Scenarios 1 and 2 are more sensitive than Scenarios 3 and 4. As the target moves further away
from that at the true OD, the %BD is aﬀected. As reﬂected in Scenarios 2 and 3, if we choose a target
below that at the true OD, the design will avoid recommending a toxic dose as the OD. It will also
not allocate toxic doses to the cohorts often. But that may have a negative impact on the correct520
identiﬁcation of the optimum dose, as in Scenario 2. Similarly, if the target is above that at the true
OD, the design may not refrain from recommending a toxic dose as the OD. Scenario 3 is not that
aﬀected by the target AUC, as the dose-response curve is more ﬂat here. Since this scenario has many
doses with similar probabilities of eﬃcacy, the target AUC chosen at any dose in the neighbourhood
of the true OD will not aﬀect the design much. In any of these four scenarios, a small misspeciﬁcation525
of the target AUC should not signiﬁcantly aﬀect the outcome of the trials.
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Table 2: Sensitivity of the design to the assumed target for the AUC.
Scenario Dose %BD %TD %AD
1 0.5 99.0 0.6 65.3
1.0 44.7 0.0 40.5
1.5 46.4 44.4 36.2
2.0 50.5 37.6 35.6
2.5 53.0 36.1 33.3
2 4.5 0.5 0.0 2.0
5.0 72.7 0.1 33.6
5.5 80.2 0.9 41.1
6.0 72.0 3.5 34.2
6.5 62.9 8.5 34.0
3 5.5 91.9 0.0 45.1
6.0 91.1 0.0 49.8
6.5 91.7 0.0 52.4
7.0 86.4 0.0 51.6
7.5 82.4 1.5 48.5
4 8.0 9.0 0.0 6.3
8.5 29.5 0.0 13.2
9.0 49.7 0.0 18.8
9.5 48.7 0.0 19.3
10.0 47.9 0.0 17.8
4. Discussion
The presented design is conceptually similar to that of Zhang et al. (2006), but their design does
not incorporate PK information. They ﬁnd a dose that maximises the diﬀerence between the estimated
probability of eﬃcacy and λ times the estimated probability of toxicity, given that the estimated prob-530
ability of toxicity is smaller than a pre-speciﬁed level, where 0 ≤ λ ≤ 1. The value of λ can be varied
to weigh the importance of toxicity in the criterion, but no recommendation is made about its value.
However, in many real scenarios, such a diﬀerence with a non-zero λ may lead to doses which are not
optimum. Therefore, we decide to use λ = 0, which also helps to avoid double dependence on the
probability of toxicity.535
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In this paper, along with dose-response outcomes, we have considered an important PK measure,
AUC, and its inter-patient variability in the dose escalation. The main purpose of this study was to
investigate the role of PK measures in dose ﬁnding and, by means of detailed comparisons, we showed
that utilising the PK information can be very beneﬁcial. The original version of Zhang et al. (2006)540
is a fully model-based procedure. To make it comparable with our design, we have employed the
up-and-down procedure in that design too. The up-and-down stage is required in our method to facil-
itate the maximum likelihood estimation of the PK model parameters. The fully model-based version
of our design should be possible if we apply the Bayesian approach to PK parameter estimation as well.
545
The PK information is commonly collected in early clinical trials and it is often analysed for the
purpose of dose selection. Here, we propose a systematic method with a two-fold aim: ﬁrst, to obtain
the best dose level for further studies in phase IIB or III trials with the minimum chance of toxic
responses during the trial and, second, to obtain the most eﬃcient estimates of the population PK
parameters. The second goal is achieved by using the population D-optimum design for the sampling550
times. A PK guided trial will make sense only if the PK information is accurate and we assure this by
the choice of design.
The simulation results from four diﬀerent dose-response scenarios indicate that the incorporation
of such measures can improve the accuracy of dose ﬁnding studies. It is also shown that the method555
is capable of limiting overdosing by a considerable amount depending on the location of the OD. The
proposed PK guided approach can therefore be used in situations where more careful escalation is
essential to avoid toxicity.
As indicated in the up-and-down stage, a trial is terminated if an unacceptable level of toxicity is560
found at the very beginning. Once the model-based procedure applies, we stop early only if the same
dose is repeated for r cohorts. At any stage, when the constraints are not satisﬁed, we allocate the
lowest dose to the next cohort. In our design, it is possible to terminate a trial early for lack of eﬃcacy
by using an additional constraint that would ensure that the selected dose has at least a prespecifed
level of eﬃcacy. Such a constraint could be used after a reasonable number of stages, as using it from565
the beginning may force the design to stop before learning much about the dose-response relationship.
The priors that have been chosen for Bayesian estimation of the dose-response parameters are
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vague enough to produce any possible extreme scenario. This reﬂects lack of knowledge of the shape
of the response curves. If it is possible to choose more informative priors, the results will improve570
even further. The information on point prior values of the PK parameters is often available, and so
we apply maximum likelihood estimation for the PK model. However, these parameters are treated as
random to allow for the variability in the population.
We have assumed a single PK proﬁle for each of the four dose-response scenarios. Though not575
presented here, we have found Scenarios 1 and 4 to be insensitive to the assumed coeﬃcient of vari-
ation for the PK parameters. The other two scenarios can be aﬀected if we increase it greatly. As
seen in (4), the variance of the AUC depends on both the PK parameters and the dose. If the dose
is small, the increase in the variance components will have a slight eﬀect on the variance of the AUC
compared to that if the dose is high. Since in Scenario 1, the true OD lies towards the beginning580
of the dose region, the impact of a change in the variance components is negligible. As there is no
dose above 10 in Scenario 4, the impact of the PK proﬁle is negligible for this scenario too. The
consideration of a 12% coeﬃcient of variation is not unrealistic in that here both mean parameters
have the same coeﬃcient of variation. The coeﬃcient of variation in one parameter is very likely to be
diﬀerent from the other in real situations and any increase will have less impact than what we have now.585
Since the proposed design is for seamless phase I/II trials, assuming a maximum sample size of 60
patients is not unreasonable. Also, an early stopping rule is in use to stop a trial if convergence to
a dose occurs. A smaller sample size can be used if a good prior distribution for the dose-response
parameters exists. Also, we have assumed 20 available doses of the experimental drug to investigate590
the properties of the method. In practice, a smaller number of dose levels may be available.
Implementation of the method requires a reliable value for the target AUC. Since we did not have
one for our example in Section 3, for simulation purposes, we set the target AUC as the one at the true
OD. In real trials for new drugs, it may be elicited from the experiences of the clinicians. Previous595
studies of similar drugs or extrapolation from pre-clinical studies of the same drug could be some
possible options as well.
Further work is needed, so that other available information can also be used to beneﬁt clinical
trials. Inclusion of covariates into the models or considering additional PD responses, such as changes600
in some biomarkers, can potentially help in capturing the variability in the observed drug action and
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so further improving the dose-selection trials. Other optimality criteria may be considered too. The
approach presented in this paper would be the same, although the level of diﬃculty of implementing
it might increase.
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Appendix A. Up-and-down design
Assume that we are at the kth stage of the up-and-down procedure of a trial and that the successive
k cohorts have received doses from a pre-speciﬁed sequence of doses X . Let us denote the proportion
of toxic responses up to cohort k by pˆk, that is,
pˆk =
1
kc
k∑
i=1
Ri2,
where c is the cohort size and Ri2 is the number of toxic responses for the ith cohort after receiving a610
dose. The algorithm starts with the lowest dose from a pre-speciﬁed sequence of ordered doses. Then
for the given thresholds pL, pM and pU , we increase, stay at the same dose level, decrease or stop
the trial depending on the value of pˆk. In the simulation study, we set pL = γ/3, pM = 2γ/3 and
pU = γ, where γ is the maximum acceptable level for the probability of toxicity. More speciﬁcally, the
algorithm has the following structure:615
pˆk

≤ pL increase the dose to the next level if not at the highest
level, otherwise stay at the highest level,
∈ (pL, pM ) stay at the current dose,
∈ [pM , pU ) decrease the dose by one level if not at the lowest
level, otherwise stay at the lowest level,
≥ pU stop the trial.
Although we have chosen the thresholds so that the width is γ/3, other choices can be made as
recommended by a clinician.
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Appendix B. Fisher information matrix for the population PK model
The Taylor series expansion gives the approximate function as
f(θi, tij) ∼= f(θi, tij)
∣∣∣∣
φ0
+
(
∂f(θi, tij)
∂φi
)T ∣∣∣∣
φ0
(φi − φ0)
= f(θi, tij)
∣∣∣∣
φ0
+
(
∂f(θi, tij)
∂β
)T ∣∣∣∣
φ0
(β − β0) +
(
∂f(θi, tij)
∂bi
)T ∣∣∣∣
φ0
(bi − 0)
= µij +
(
∂f(θi, tij)
∂β
)T ∣∣∣∣
φ0
β +
(
∂f(θi, tij)
∂bi
)T ∣∣∣∣
φ0
bi,
where µij is a constant. Writing this in matrix notation for ni observations, we have a linear mixed
eﬀects model for individual i given by
yi ∼= µi +Hiβ +Libi + i,
where Hi = (∂f(θi, tij)/∂β)
T ∣∣
φ0
and Li = (∂f(θi, tij)/∂bi)
T ∣∣
φ0
are (ni × p)-dimensional matrices,
µi is the vector of constants µij and i is the vector of random errors ij . This gives
Ei = E(yi) ∼= µi +Hiβ,
and, by the assumption of independence of bi and i, we have
Vi = Var(yi) ∼= LiΩLTi + Σi,
where Σi is an ni × ni diagonal matrix with all the diagonal elements equal to σ2.620
Since bi and i are assumed to be normal, the log-likelihood function is approximated by
`i(Ψ | yi) ∼= log
[
(2pi)−
ni
2 |Vi|− 12 exp
{
−1
2
(yi −Ei)TV −1i (yi −Ei)
}]
.
Then the FIM for individual i can be approximated by the block diagonal matrix
Mi(Ψ, ξi) ∼=
 Ai 0
0 Bi
 ,
where elements (m,n) of Ai and Bi have the forms
(Ai)mn =
(
∂Ei
∂βm
)T
V −1i
∂Ei
∂βn
for m,n = 1, . . . , p
and
(Bi)mn =
1
2
tr
(
∂Vi
∂λm
V −1i
∂Vi
∂λn
V −1i
)
for m,n = 1, . . . , p+ 1.
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Appendix C. Calculation of the approximate mean and variance of the AUC
The ﬁrst-order Taylor series expansion of h(x,θi) about θi at E(θi) gives625
h(x,θi) ∼= h(x,θi)
∣∣∣∣
E(θi)
+
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
(θi − E(θi))
= h(x,β) +
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
bi,
where E(θi) = β. Therefore,
E{h(x,θi)} ∼= h(x,β)
and
Var{h(x,θi)} ∼=
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂h(x,θi)
∂θi
) ∣∣∣∣
E(θi)
.
For our PK model, the AUC for an individual i over the range [0, t1] is deﬁned as
h(x,θi) =
∫ t1
0
f(θi, t) dt
=
∫ t1
0
x
Vi
exp
(
−Cli
Vi
t
)
dt
=
x
Cli
{
1− exp
(
−Cli
Vi
t1
)}
.
Assuming that E(Vi) = V and E(Cli) = Cl, we obtain
E{h(x,θi)} ∼= h(x,β) = x
Cl
{
1− exp
(
−Cl
V
t1
)}
and
Var{h(x,θi)} ∼=
(
∂h(x,θi)
∂θi
)T ∣∣∣∣
E(θi)
Ω
(
∂h(x,θi)
∂θi
) ∣∣∣∣
E(θi)
=
(
∂h(x,θi)
∂Vi
∂h(x,θi)
∂Cli
)
E(θi)
 ω1 0
0 ω2
 ∂h(x,θi)∂Vi
∂h(x,θi)
∂Cli

E(θi)
=
{
∂h(x,θi)
∂Vi
∣∣∣∣
E(θi)
}2
ω1 +
{
∂h(x,θi)
∂Cli
∣∣∣∣
E(θi)
}2
ω2.
Also, we have
∂h(x,θi)
∂Vi
∣∣∣∣
E(θi)
= −xt1
V 2
exp
(
−Cl
V
t1
)
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and630
∂h(x,θi)
∂Cli
∣∣∣∣
E(θi)
=
x
Cl
exp
(
−Cl
V
t1
)(
1
Cl
+
t1
V
)
− x
Cl2
.
It follows that
Var{h(x,θi)} ∼=
{
−xt1
V 2
exp
(
−Cl
V
t1
)}2
ω1 +
{
x
Cl
exp
(
−Cl
V
t1
)(
1
Cl
+
t1
V
)
− x
Cl2
}2
ω2.
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